The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. METHODS: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. RESULTS: At the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cholesterol levels. Patients were followed for a median of 31 months. At a prespecified interim analysis that included 1135 primary end-point events (71% of the projected total number), the independent data and safety monitoring board recommended termination of the trial for futility. As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, respectively; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P=0.52) and did not have a significant effect on any component of the primary end point or total mortality. The median C-reactive protein level was 0.2 mg per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons). CONCLUSIONS: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last factor probably also contributed to the rise in LDL cholesterol observed in the placebo group, in the on-treatment analysis in the alirocumab group, and in previous trials involving patients who had an acute coronary syndrome. 5,21”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, early generations of CETP inhibitors were either associated with off-target adverse effects with safety concerns, or had no significant or only modest LDL-C lowering and thus failed to demonstrate cardiovascular benefit, leading to a loss of enthusiasm in this drug class [[7], [8], [9], [10]].”
From Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Anacetrapib reduced major coronary events by 9% over a median of 4.1 years [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“More recently, the REVEAL study investigated anacetrapib in > 30 000 patients with atherosclerotic vascular disease and resulted in a lower incidence of MACE compared with placebo after 4 years, with no safety concerns [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events. 362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events.362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [85]
In the citing paper
“However, three out of four prospective studies with CETP inhibitors had to be terminated due to increased mortality in the treatment group or due to futility (Table 3).”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [107]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Yavorska, O. O., & Burgess, S. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx034 · Cited by 2,029
Authors Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,994
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citationHerrington, W. G., Lacey, B., Sherliker, P., Armitage, J., & Lewington, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.307611 · Cited by 1,528
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association
Sacks, F. M., Lichtenstein, A. H., Wu, J. H. Y., Appel, L. J., Creager, M. A., Kris-Etherton, P. M., Miller, M., Rimm, E. B., Rudel, L. L., Robinson, J. G., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000510 · Cited by 1,386
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
Recent Developments in Mendelian Randomization Studies
Zheng, J., Baird, D. A., Borges, M. C., Bowden, J., Hemani, G., Haycock, P., Evans, D. M., & Smith, G. D. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0128-6 · Cited by 1,147
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Cardiovascular Effects and Benefits of Exercise
Nystoriak, M. A., & Bhatnagar, A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00135 · Cited by 968
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Self-citationEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Self-citationMendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Vlachopoulos, C., Xaplanteris, P., Aboyans, V., Brodmann, M., Cífková, R., Cosentino, F., De Carlo, M., Gallino, A., Landmesser, U., Laurent, S., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.007 · Cited by 716
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Holmes, M. V., Dale, C. E., Zuccolo, L., Silverwood, R. J., Guo, Y., Ye, Z., Prieto-Merino, D., Dehghan, A., Trompet, S., Wong, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4164 · Cited by 669
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., Huikuri, H., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Vlachopoulos, C. V., Xaplanteris, P., Aboyans, V., Brodmann, M., Cífková, R., Cosentino, F., Carlo, M. D., Gallino, A., Landmesser, U., Laurent, S., et al. (2015) · HAL · Cited by 590
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Lüscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 568
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality
Evans, D. M., & Smith, G. D. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050016 · Cited by 529
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I. A., & Tao, W. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 544
Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 513
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Fox, C. S., Golden, S. H., Anderson, C. A. M., Bray, G. A., Burke, L. E., de Boer, I. H., DEEDWANIA, P. C., Eckel, R. H., Ershow, A. G., FRADKIN, J. E., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 504
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 505
Saleheen, D., Scott, R. A., Javad, S., Zhao, W., Rodrigues, A., Picataggi, A., Lukmanova, D., Mucksavage, M. L., Luben, R., Billheimer, J. T., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00126-6 · Cited by 479
Nardo, D. D., Labzin, L. I., Kono, H., Seki, R., Schmidt, S. V., Beyer, M., Xu, D., Zimmer, S., Lahrmann, C., Schildberg, F. A., et al. (2013) · Nature Immunology · doi:10.1038/ni.2784 · Cited by 477
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 469
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Driest, S. L. V. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 455
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Self-citationThe TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance
Warrier, M., Shih, D. M., Burrows, A. C., Ferguson, D., Gromovsky, A. D., Brown, A. L., Marshall, S., McDaniel, A., Schugar, R. C., Wang, Z., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.036 · Cited by 414
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
Hankey, G. J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70255-2 · Cited by 399
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
PET imaging of inflammation in atherosclerosis
Tarkin, J. M., Joshi, F. R., & Rudd, J. H. F. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.80 · Cited by 388
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
SHAH, A. S., Tan, L., Long, J. L., & Davidson, W. S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r035725 · Cited by 359
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Self-citationKo, D. T., Alter, D. A., Guo, H., Koh, M., Lau, G., Austin, P. C., Booth, G. L., Hogg, W. E., Jackevicius, C. A., Lee, D. S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.038 · Cited by 340
Using Mendelian Randomization to Improve the Design of Randomized Trials
Ference, B. A., Holmes, M. V., & Smith, G. D. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040980 · Cited by 338
HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research
Rohatgi, A. K., Westerterp, M., von Eckardstein, A., Remaley, A. T., & Rye, K. (2021) · Circulation · doi:10.1161/circulationaha.120.044221 · Cited by 353
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Speer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310
Mendelian randomization: where are we now and where are we going?
Burgess, S., Timpson, N. J., Ebrahim, S. B. J., & Smith, G. D. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv108 · Cited by 313
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2017) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 311
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304
Self-citationChoy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z., & Nurmohamed, M. T. (2014) · Rheumatology · doi:10.1093/rheumatology/keu224 · Cited by 310
Cardioprotective functions of HDLs
Rye, K., & Barter, P. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r039297 · Cited by 310
Self-citationAssociation of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W., Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1884 · Cited by 293
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 299
Tarkin, J. M., Dweck, M. R., Evans, N. R., Takx, R. A. P., Brown, A. J., Tawakol, A. A., Fayad, Z. A., & Rudd, J. H. F. (2016) · Circulation Research · doi:10.1161/circresaha.115.306247 · Cited by 290
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Pathophysiology and treatment of atherosclerosis
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 299
HDL cholesterol: reappraisal of its clinical relevance
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1106-1 · Cited by 275
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 281
Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272
Self-citationApolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., Leon, J. D., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 299
Afzal, S., Brøndum-Jacobsen, P., Bojesen, S. E., & Nordestgaard, B. G. (2014) · BMJ · doi:10.1136/bmj.g6330 · Cited by 277
ATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation
Westerterp, M., Bochem, A. E., Yvan‐Charvet, L., Murphy, A. J., Wang, N., & Tall, A. R. (2014) · Circulation Research · doi:10.1161/circresaha.114.300738 · Cited by 261
Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251
Self-citationMechanisms and the Evidence Hierarchy
Clarke, B., Gillies, D., Illari, P., Russo, F., & Williamson, J. (2014) · Topoi · doi:10.1007/s11245-013-9220-9 · Cited by 253
Helgadóttir, A., Grétarsdóttir, S., Þorleifsson, G., Hjartarson, E., Sigurðsson, Á., Magnusdottir, A., Jónasdóttir, Á., Kristjansson, H., Sulem, P., Oddsson, Á., et al. (2016) · Nature Genetics · doi:10.1038/ng.3561 · Cited by 248
Webb, T. R., Erdmann, J., Stirrups, K. E., Stitziel, N. O., Masca, N. G. D., Jansen, H., Kanoni, S., Nelson, C. P., Ferrario, P. G., König, I. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.056 · Cited by 250
Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
Jin, Q., & Ma, R. C. W. (2021) · Cells · doi:10.3390/cells10112832 · Cited by 252
Varbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
High-density lipoproteins, reverse cholesterol transport and atherogenesis
Pownall, H. J., Rosales, C., Gillard, B. K., & Gotto, A. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00538-z · Cited by 266
Liu, C., Dhindsa, D., Almuwaqqat, Z., Ko, Y.-A., Mehta, A., Alkhoder, A. A., Alras, Z., Desai, S. R., Patel, K. J., Hooda, A., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0912 · Cited by 250
The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease
Ruiz-Núñez, B., Dijck-Brouwer, J., & Muskiet, F. A. J. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.12.007 · Cited by 249
Hovingh, G. K., Kastelein, J. J. P., van Deventer, S. J. H., Round, P., Ford, J., Saleheen, D., Rader, D. J., Brewer, H. B., & Barter, P. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60158-1 · Cited by 240
Self-citationMora, S., Glynn, R. J., & Ridker, P. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002671 · Cited by 241
pre-diabetes Task Force on diabetes (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 239
Lymphatic transport of high-density lipoproteins and chylomicrons
Randolph, G. J., & Miller, N. E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71610 · Cited by 233
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.004 · Cited by 239
Functional significance of cholesterol metabolism in cancer: from threat to treatment
Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Li, J., Xu, H., Zhao, Y., Yu, X., & Shi, S. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01079-w · Cited by 260
Lincoff, A. M., Tardif, J., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B. C., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 232
Self-citationKosmas, C. E., Martinez, I., Sourlas, A., Bouza, K. V., Campos, F. N., Torres, V., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212525 · Cited by 248
Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products
Wang, D., Yang, Y., Lei, Y., Tzvetkov, N. T., Liu, X., Yeung, A. W. K., Xu, S., & Atanasov, A. G. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017178 · Cited by 223
Translation of High-Density Lipoprotein Function Into Clinical Practice
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P. J., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2013) · Circulation · doi:10.1161/circulationaha.113.000962 · Cited by 225
Self-citationKhera, A. V., Demler, O., Adelman, S. J., Collins, H. L., Glynn, R. J., Ridker, P. M., Rader, D. J., & Mora, S. (2017) · Circulation · doi:10.1161/circulationaha.116.025678 · Cited by 226
Metadata
- Authors
- Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Mundl, H., Nicholls, S. J., Shah, P. K., Tardif, J.-C., & Wright, R. S.
- Affiliations
- Denver VA Medical Center (US)
- Linköping University (SE)
- F. Hoffmann-La Roche AG (CH)
- Baylor College of Medicine (US)
- University of Zurich (CH)
- Oslo University Hospital (NO)
- St. Michael's Hospital (CA)
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-11-29
- Volume
- 367
- Issue
- 22
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118825330
- Cited by
- 2,022
- References
- 35
- Citations by year
- 2026: 66 · 2025: 82 · 2024: 81 · 2023: 89 · 2022: 103 · 2021: 128 · 2020: 109 · 2019: 141 · 2018: 164 · 2017: 195 · 2016: 222 · 2015: 244 · 2014: 191 · 2013: 190 · 2012: 7
- FWCI
- 206.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche
- CSL Behring
- Amarin Corporation
- Anthera
- Kowa Company
- Servier
- Esperion Therapeutics
- Genentech
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- dalcetrapib, cholesteryl ester transfer protein inhibition, HDL cholesterol, acute coronary syndrome, cardiovascular risk, futility, LDL cholesterol, C-reactive protein, systolic blood pressure, myocardial infarction, ischemic stroke, unstable angina, cardiovascular mortality, lipid-lowering therapy
- MeSH terms
- Aged, Amides, Anticholesteremic Agents, Apolipoproteins, Blood Pressure, C-Reactive Protein, Cardiovascular Diseases, Esters, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Sulfhydryl Compounds, Triglycerides, Biomarkers, Cholesterol Ester Transfer Proteins, Acute Coronary Syndrome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
